Lycia Therapeutics Has Filed for Public Offering
The biotech firm seeks to fund development of its protein-degradation platform following positive Phase I trial results.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Is the current surge in biotech IPOs a sign of a healthy innovation sector?
Lycia Therapeutics has filed for an initial public offering in the United States to accelerate its clinical pipeline. The move follows a $75 million Series D funding round completed just three months ago.
Why it matters
The company intends to use the capital to advance a suite of therapeutics designed to degrade extracellular proteins, a novel approach to treating multiple conditions.
The lead drug candidate LCA-0061 targets extracellular IgE for lysosomal degradation, showing effects lasting 28 days post-dose. No safety signals or dose-limiting toxicities were observed during the study.
The players
Lycia Therapeutics
This biotechnology firm specializes in developing therapies that utilize lysosomal degradation to target proteins.
Carolyn Bertozzi
A prominent scientist and Nobel laureate, she co-founded Lycia Therapeutics in 2019.
Lilly
This major pharmaceutical corporation has maintained a multi-year partnership with Lycia, including a 2021 discovery deal.
Versant Ventures
A life sciences investment firm that provided the initial $50 million in funding to launch Lycia.
TRex Bio
A peer biotechnology firm currently planning a separate $125 million initial public offering.
The details
Co-founded by Carolyn Bertozzi in 2019, the firm emerged from stealth in 2020 with $50 million in backing. Its pipeline includes the thyrotropin receptor antibody degrader LCA-0321 and the preclinical candidate LCA-0062.
Timeline
2019: Lycia Therapeutics was co-founded.
2020: The company emerged from stealth mode.
2021: Lilly signed a discovery deal with Lycia.
2024: Lilly backed a $106.6 million series C funding round.
October 5, 2026: Lycia Therapeutics filed for an initial public offering.
The Tech Race
This move highlights the intensifying competition in the protein-degradation sector, which is evolving to replace traditional antibody-based therapies. It positions Lycia among a group of emerging biotech firms racing to capitalize on proprietary degraders.
Investors can monitor the IPO filing to evaluate the future availability of new targeted therapies for immune-related disorders. The success of this offering may determine the speed at which these advanced treatments reach the clinical pipeline.
The takeaway
The successful Phase I data provides a critical proof-of-concept for the firm's extracellular protein degradation technology. As the company moves toward public trading, its ability to translate these early results into long-term clinical efficacy will be the primary focus for stakeholders.
Further reading
For more on market trends, visit the /tech/biotech/ section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Is the current surge in biotech IPOs a sign of a healthy innovation sector?
